Drug
31 Valent Pneumococcal Conjugate Vaccine
31 Valent Pneumococcal Conjugate Vaccine: highest development phase Phase 3, developed by Vaxcyte, Inc.. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Vaxcyte, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| 31-valent pneumococcal conjugate vaccine NCT07365826 | Phase 3 | Pneumococcal Disease |
| 31-valent pneumococcal conjugate vaccine NCT07425392 | Phase 3 | Pneumococcal Disease |
Latest
No recent events.
Follow 31 Valent Pneumococcal Conjugate Vaccine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.